Literature DB >> 18438725

Bisphosphonate delivery to tubular bone allografts.

Gene R DiResta1, Mark W Manoso, Anwar Naqvi, Pat Zanzonico, Peter Smith-Jones, Wakenda Tyler, Carol Morris, John H Healey.   

Abstract

Large structural allografts used for reconstruction of bone defects after revision arthroplasty and tumor resection fracture up to 27% of the time from osteolytic resorption around the fixation screw holes and tendon or ligament attachment sites. Treating structural allografts before implantation with bisphosphonates may inhibit local osteoclastic processes and prevent bone resorption and the development of stress risers, thereby reducing the long-term fracture rate. Taking advantage of allografts' open-pore structure, we asked whether passive soaking or positive-pressure pumping was a more efficient technique for delivering bisphosphonates. We treated matched pairs of ovine tibial allografts with fluids containing Tc-99m pamidronate and toluidine blue stain to facilitate indicator distribution analysis via microSPECT-microCT imaging and light microscopy, respectively. Surfactants octylphenoxy polyethoxy ethanol or beractant were added to the treatment fluids to reduce flow resistance of solutions pumped through the allografts. Indicator distribution after 1 hour of soaking produced a thin ring around periosteal and endosteal surfaces, while pumping for 10 minutes produced a more even distribution throughout the allograft. Flow resistance was reduced with octylphenoxy polyethoxy ethanol but unaffected with beractant. Pumped allografts displayed a more homogeneous indicator distribution in less time than soaking while surfactants enhanced fluid movement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438725      PMCID: PMC2584260          DOI: 10.1007/s11999-008-0259-7

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  24 in total

1.  Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate.

Authors:  Divesh Kumar; Vijay Kumar; David G Little; Robert B Howman-Giles; Effie Wong; Sinan O Ali
Journal:  J Orthop Sci       Date:  2006-10       Impact factor: 1.601

2.  Soaking morselized allograft in bisphosphonate can impair implant fixation.

Authors:  Thomas Jakobsen; Jørgen Baas; Joan E Bechtold; Brian Elmengaard; Kjeld Søballe
Journal:  Clin Orthop Relat Res       Date:  2007-10       Impact factor: 4.176

3.  The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.

Authors:  S R Frenkel; W L Jaffe; C D Valle; L Jazrawi; S Maurer; A Baitner; K Wright; D Sala; M Hawkins; P E Di Cesare
Journal:  J Biomed Mater Res       Date:  2001

4.  1983 bone bank procedures.

Authors:  W W Tomford; S H Doppelt; H J Mankin; G E Friedlaender
Journal:  Clin Orthop Relat Res       Date:  1983-04       Impact factor: 4.176

Review 5.  Porosity and specific surface of bone.

Authors:  R B Martin
Journal:  Crit Rev Biomed Eng       Date:  1984

6.  Bone allografts pretreated with a bisphosphonate are not resorbed.

Authors:  Per Aspenberg; Jörgen Astrand
Journal:  Acta Orthop Scand       Date:  2002-01

7.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

Review 9.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

10.  Clostridium infections associated with musculoskeletal-tissue allografts.

Authors:  Marion A Kainer; Jeanne V Linden; David N Whaley; Harvey T Holmes; William R Jarvis; Daniel B Jernigan; Lennox K Archibald
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

View more
  4 in total

1.  Distribution of locally delivered antimicrobials is limited by cortical bone: a pilot study.

Authors:  Ryan Odgers; Keith Jarbo; Alex McLaren; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

2.  Intercalary allograft reconstructions using a compressible intramedullary nail: a preliminary report.

Authors:  Benjamin J Miller; Walter W Virkus
Journal:  Clin Orthop Relat Res       Date:  2010-02-10       Impact factor: 4.176

3.  Antimicrobial distribution from local delivery depends on dose : a pilot study with MRI.

Authors:  Alex McLaren; Morgan B Giers; James Fraser; Luke Hosack; Michael R Caplan; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2014-11       Impact factor: 4.176

4.  Effect of low-level laser therapy on incorporation of block allografts.

Authors:  Renato Valiati; Jefferson Viapiana Paes; Aury Nunes de Moraes; Aldo Gava; Michelle Agostini; Anelise Viapiana Masiero; Marilia Gerhardt de Oliveira; Rogério Miranda Pagnoncelli
Journal:  Int J Med Sci       Date:  2012-11-05       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.